Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of “Hold” by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given a consensus rating of “Hold” by the nine analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.63.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th.

Fulcrum Therapeutics Stock Down 4.3 %

Shares of NASDAQ FULC opened at $2.88 on Tuesday. Fulcrum Therapeutics has a twelve month low of $2.78 and a twelve month high of $10.13. The company has a market cap of $155.46 million, a PE ratio of -9.29 and a beta of 2.20. The business’s 50 day moving average price is $3.50 and its two-hundred day moving average price is $3.68.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). As a group, research analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new position in shares of Fulcrum Therapeutics during the fourth quarter worth approximately $38,000. Walleye Capital LLC acquired a new position in Fulcrum Therapeutics in the 3rd quarter valued at $59,000. Intech Investment Management LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter valued at $62,000. Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth $78,000. Finally, Cantor Fitzgerald L. P. bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth $94,000. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.